Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06100263
Other study ID # UMCC 2023.092
Secondary ID HUM00244376
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2024
Est. completion date December 2026

Study information

Verified date June 2024
Source University of Michigan Rogel Cancer Center
Contact Cancer AnswerLine
Phone 1-800-865-1125
Email CancerAnswerLine@med.umich.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will use a cross-sectional study design with a follow-up 2-arm randomized controlled trial with that has assessments at baseline, post-intervention (i.e., Week 12), and 3-months post-intervention (i.e., Week 24). The 2 arms are the 12-week intervention and a health education control among 60 Black breast cancer survivors.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date December 2026
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: Women will be eligible if they meet the following criteria: - self-identify as Black or African American or Afro-Latina/e; - are =18 years old; - have a confirmed diagnosis of breast cancer, Stage 0I to IIIA; - have completed primary active treatment (i.e., surgery, chemotherapy, and radiation) within 5 years prior to study start where concomitant hormonal therapy is acceptable; - are not meeting current cancer-specific resistance exercise guidelines of = 2 times per week; and - are able to speak and understand English. Exclusion Criteria: - metastatic disease; - medical reason that precludes them from increasing current exercise levels; - planned elective surgery during study period; - pregnant or plans to become pregnant during the study period; - plans to move out of United States during the study period; (the rationale for this exclusion is that it will be difficult to conduct the in-person assessments if a participant leaves the United States); - current enrollment in another exercise trial; and/or - inability to pass exercise pre-screening or receive physician consent to increase current physical activity levels.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Individualized exercise program
guided exercise program for 12 weeks
Control Arm
American Cancer Society Physical Activity and the Person with Cancer summary for patients will be provided

Locations

Country Name City State
United States University of Michigan Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan Rogel Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility of the exercise program (Retention) Percent of patients that complete the intervention up to 24 weeks after start of intervention
Primary Feasibility of the exercise program (Adherence) Percent of patients that complete the exercise sessions 12 weeks after start of intervention
Primary Feasibility of the exercise program (fidelity) Upon completion of the trial, a random sample of 10 recorded sessions will be analyzed for fidelity. Research staff who did not conduct the intervention will use a "fidelity checklist" of specific exercises and intervention characteristics (e.g., allowing time for questions, cueing for proper posture and form, etc.) required for each exercise session.. 12 weeks after start of intervention
Primary Satisfaction of program 14-item scale measuring ease of use, convenience, engagement, enjoyment, and privacy elements of the intervention. up to 24 weeks after start of intervention
Primary Affective attitude 36-item scale assessing views, attitude, and experiences in exercise87 up to 24 weeks after start of intervention
Primary Perceived burden Single item, "Now that you've completed this part of the study, how burdensome or difficult did you find the experience. Select the response that best represents your experience." (1= Very burdensome to 5= Not too burdensome.) up to 24 weeks after start of intervention
Primary Outcome expectation 15-item scale assessing physical, social, and self-evaluative outcomes of exercise up to 24 weeks after start of intervention
See also
  Status Clinical Trial Phase
Completed NCT03080623 - Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion
Completed NCT05527769 - Pain and Functional Recovery After Mastectomy and IBR by Implant: Prepectoral Versus Subpectoral Technique
Completed NCT06376578 - Exercise Interventions for Improving Health in Breast Cancer Survivors N/A
Completed NCT03004534 - A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide Early Phase 1
Recruiting NCT05020574 - Microbiome and Association With Implant Infections Phase 2
Active, not recruiting NCT06277141 - The Vitality Mammography Messaging Study N/A
Completed NCT03270111 - High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women N/A
Completed NCT03555227 - USG PECS vs LIA for Breast Cancer Surgery N/A
Active, not recruiting NCT03917082 - Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer Phase 2
Recruiting NCT05561842 - Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
Completed NCT04554056 - Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF Phase 2/Phase 3
Active, not recruiting NCT03127995 - Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence N/A
Active, not recruiting NCT02237469 - Prone Breast Radiotherapy Treatment Planning Observational Study
Completed NCT01204125 - Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients Phase 2
Recruiting NCT04565054 - Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC Phase 3
Not yet recruiting NCT06412133 - Conversations in Light and Shadow: Assessing Phototherapy's Impact on Breast Cancer Patients N/A
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Recruiting NCT06087120 - Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting NCT06058936 - Exercises Using Virtual Reality on Cancer Patients N/A
Completed NCT03470935 - Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger